99001802-2
IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07K 16/46, A61K 39/395, 38/19, 35/14, G01N 33/68 // C07K 16/28, 16/32, 16/30, 14/33, 16/14, (A61K 39/395, 38:19)

A1

(11) International Publication Number: **WO 98/02463**

(43) International Publication Date: 22 January 1998 (22.01.98)

(21) International Application Number: PCT/US97/12013

(22) International Filing Date: 10 July 1997 (10.07.97)

(30) Priority Data:
08/678,194 11 July 1996 (11.07.96) US

(60) Parent Application or Grant
(63) Related by Continuation
US 08/678,194 (CIP)
Filed on 11 July 1996 (11.07.96)

(71) Applicant *(for all designated States except US)*: MEDAREX, INC. [US/US]; 1545 Route 22 East, P.O. Box 992, Annandale, NJ 08801-0992 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: DEO, Yashwant, M. [US/US]; 3009 Peacock Drive, Audubon, PA 19403 (US). GRAZIANO, Robert [US/US]; 1046 County Road, Route 519, Frenchtown, NJ 08825 (US). KELER, Tibor [US/US]; 30 Park Road, Ottsville, PA 18942 (US).

(74) Agents: DECONTI, Giulio, A., Jr. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: THERAPEUTIC MULTISPECIFIC COMPOUNDS COMPRISED OF ANTI-FCα RECEPTOR ANTIBODIES

(57) Abstract

Multispecific compounds comprising at least one binding determinant which binds to the Fcx-receptor on an effector cell. The other binding determinant(s) binds(s) to one or more antigens on a target cell, e.g., the Neu/Her-2 proto-oncogene product or the epidermal growth factor receptor on cancer cells, or to Candida antigens on infected cells. Examples are biospecific and trispecific antibodies. Therapeutic use of said multispecific compounds for treatment of cancers or pathogen infections.

